Test Identifies Women at Risk for Clots While on Tamoxifen

Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Saturday, October 1, 2005

Use of tamoxifen to prevent breast cancer recurrences has long been associated with an increased risk of developing blood clots. It appears, however, that women who take tamoxifen and have the Factor V Leiden (FVL) genetic mutation may have an even higher risk of clots compared to women taking tamoxifen who do not carry this mutation. Factor V Leiden is the most common hereditary coagulation disorder. It affects approximately 5% of the Caucasian population.

A study of >300 women, conducted at Yale University School of Medicine, revealed that women who developed blood clots while on tamoxifen were 4 times as likely to carry the FVL mutation. The researchers concluded that their results suggest that testing women for FVL prior to adjuvant therapy may enable physicians to investigate alternatives to tamoxifen or prescribe blood thinners during treatment of women at high risk of clot development.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues